Skip to main content
Fig. 16 | AAPS Open

Fig. 16

From: Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections

Fig. 16

Dissolution of 1 mM Yomesan in nominally 9.23 Tris-buffered saline solution (TBSS): supernatant niclosamide concentration (µM) vs. time after addition (mins), baseline-corrected, 30 s corrected for, A 0–180 min. B Same data including day 2. Dashed line is the logarithmic fit to the initial (white symbol) dissolution; dotted line is to guide the eye

Back to article page